FDA Science Board Advisory Committee Meeting

April 15, 2005

5630 Fishers Lane, Room 1066

8:30 a.m. Call to Order

Kenneth I. Shine, M.D., Chair, FDA Science Board

8:40 a.m. Welcome and opening remarks

Lester M. Crawford, D.V.M., Ph.D., Acting Commissioner of Food and Drugs Janet Woodcock, M.D., Acting Deputy Commissioner for Operations, FDA

9:10 a.m. Introduction to Drug Safety

Steven K. Galson, M.D., Acting Director, Center for Drug Evaluation and Research, FDA

9:20 a.m. Pre-Market Drug Safety

Armando Oliva, M.D., Associate Director for Policy, Office of New Drugs, Center for Drug Evaluation and Research, FDA

9:40 a.m. Improvements in Drug Safety Information

Labeling and Electronic Initiatives

Rachel E. Behrman, M.D., M.P.H., Deputy Director, Office of Medical Policy, Center for Drug Evaluation and Research, FDA

Drug Safety Initiative

Steven K. Galson, M.D., Acting Director, Center for Drug Evaluation and Research, FDA

10:20 a.m. Break

11:00 a.m.

10:40 a.m. Post-Market Drug Safety

Paul J. Seligman, M.D., M.P.H., Director, Office of Drug Safety, Center for Drug Evaluation and Research, FDA

Theresa M. Mullin, Ph.D., Assistant Commissioner for Planning, FDA

11:15 a.m. Applying New Science to Drug Safety

Drug Safety Resources

Janet Woodcock, M.D., Acting Deputy Commissioner for Operations, FDA

11:30 a.m. Committee Questions and Discussion

12:30 p.m. Lunch

1:30 p.m. Open Public Hearing

2:30 p.m. Safety Systems for Vaccines, Blood and Tissues

Jesse L. Goodman, M.D., M.P.H., Director, Center for Biologics Evaluation and

Research, FDA

3:00 p.m. Committee Questions and Discussion

3:15 p.m. cGMPs for Vaccines

Mary Malarkey, B.S., Director, Office of Compliance and Biologics Quality,

Center for Biologics Evaluation and Research, FDA

3:45 p.m. Committee Questions and Discussion

4:30 p.m. Adjourn